COVID-19 and cardiovascular complications – the preliminary results of the LATE-COVID study

Abstract

IntroductionCoronavirus Disease 2019 (COVID-19) may affect many organs and may be responsible for numerous complications including cardiovascular problems.Material and methodsWe analysed consecutive patients (n=51) admitted to the cardiology department between 1st October 2020 and 31st January 2021 due to symptoms, which might have reflected cardiovascular complications following COVID-19.ResultsThe complications after Covid-19 appeared after 1-4 months after disease recovery.ConclusionsDiabetes, elevated level of CRP and troponin, heart rate variability parameters and worsening of left ventricular ejection fraction are related to the severity of cardiovascular complications following the COVID-19 infection.

2021 PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on the diagnosis and therapy of lipid disorders in Poland

“…Study results also indicate at least neutral effect of statins on the risk of development and the course of COVID-19. In contrast, the number of studies indicating their very important role, improving the prognosis not only in the course of COVID-19, but also after recovery, in the socalled Long-Covid period (> 12 weeks after recovery), is increasing [402]. This is associated with the mechanisms of action of statins, not only their anti-inflammatory and anti-oxidative properties, stabilising atherosclerotic plaque (especially during the so-called cytokine storm), but also inhibition of the main coronavirus protease, reduction of the availability of lipid structural components of the virus envelope, degradation of so-called viral lipid rafts, or inhibition of its replication [403][404][405].…”

PoLA/CFPiP/PCS/PSLD/PSD/PSH guidelines on diagnosis and therapy of lipid disorders in Poland 2021

“…Study results also indicate at least neutral effect of statins on the risk of development and the course of COVID-19. In contrast, the number of studies indicating their very important role, improving the prognosis not only in the course of COVID-19, but also after recovery, in the so-called Long-Covid period (> 12 weeks after recovery), is increasing [ 402 ]. This is associated with the mechanisms of action of statins, not only their anti-inflammatory and anti-oxidative properties, stabilising atherosclerotic plaque (especially during the so-called cytokine storm), but also inhibition of the main coronavirus protease, reduction of the availability of lipid structural components of the virus envelope, degradation of so-called viral lipid rafts, or inhibition of its replication [ 403 – 405 ].…”

Nutraceuticals for the Control of Dyslipidaemias in Clinical Practice

“…However, despite the great success of conventional approaches to therapeutics, an enormous disease burden remains. Moreover, in many highly developed countries we may observe a plateau, or even a slight reduction in life expectancy in recent years, which may only be partly attributable to the coronavirus pandemic [ 4 , 5 ].…”